Harvard Bioscience, Inc.

NasdaqGM:HBIO Rapporto sulle azioni

Cap. di mercato: US$130.4m

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Harvard Bioscience Gestione

Gestione criteri di controllo 2/4

Harvard Bioscience's Il CEO è Jim Green, nominato in Jul2019, e ha un mandato di 5.08 anni. la retribuzione annua totale è $ 2.39M, composta da 24.5% di stipendio e 75.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 4.38% delle azioni della società, per un valore di $ 5.63M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2 anni e 6.8 anni.

Informazioni chiave

Jim Green

Amministratore delegato

US$2.4m

Compenso totale

Percentuale dello stipendio del CEO24.5%
Mandato del CEO5.1yrs
Proprietà del CEO4.4%
Durata media del management2yrs
Durata media del Consiglio di amministrazione6.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Harvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of Debt

Aug 07
Harvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of Debt

Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares Not Telling The Full Story

Jul 15
Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares Not Telling The Full Story

Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely

Dec 22
Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely

Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price

Sep 23
Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price

Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Aug 10
Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued

Apr 26
An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued

Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt

Apr 11
Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt

Harvard Bioscience GAAP EPS of $0.05 beats by $0.06, revenue of $29.2M misses by $1.2M

Aug 04

Harvard Bioscience (NASDAQ:HBIO) Takes On Some Risk With Its Use Of Debt

Jun 08
Harvard Bioscience (NASDAQ:HBIO) Takes On Some Risk With Its Use Of Debt

Harvard Bioscience - Dressed Up And Waiting For A Suitor

Mar 15

Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Manage Its Debt Responsibly

Feb 16
Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Manage Its Debt Responsibly

Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?

Nov 04
Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?

Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Trading At A 37% Discount?

Oct 01
Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Trading At A 37% Discount?

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 25% Undervalued

May 04
An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 25% Undervalued

These 4 Measures Indicate That Harvard Bioscience (NASDAQ:HBIO) Is Using Debt Extensively

Apr 19
These 4 Measures Indicate That Harvard Bioscience (NASDAQ:HBIO) Is Using Debt Extensively

Analysts Are Optimistic We'll See A Profit From Harvard Bioscience, Inc. (NASDAQ:HBIO)

Apr 04
Analysts Are Optimistic We'll See A Profit From Harvard Bioscience, Inc. (NASDAQ:HBIO)

Have Insiders Sold Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Recently?

Mar 20
Have Insiders Sold Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Recently?

What Kind Of Shareholders Hold The Majority In Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares?

Mar 07
What Kind Of Shareholders Hold The Majority In Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares?

Harvard Bioscience (NASDAQ:HBIO) Shareholders Have Enjoyed A 92% Share Price Gain

Feb 17
Harvard Bioscience (NASDAQ:HBIO) Shareholders Have Enjoyed A 92% Share Price Gain

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 35% Undervalued

Feb 02
An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 35% Undervalued

Have Insiders Been Buying Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares This Year?

Jan 15
Have Insiders Been Buying Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares This Year?

Harvard Bioscience: Wait For The Green Shoots Of Improvement

Jan 12

When Will Harvard Bioscience, Inc. (NASDAQ:HBIO) Become Profitable?

Dec 28
When Will Harvard Bioscience, Inc. (NASDAQ:HBIO) Become Profitable?

Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?

Dec 11
Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Jim Green rispetto agli utili di Harvard Bioscience?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

-US$11m

Mar 31 2024n/an/a

-US$9m

Dec 31 2023US$2mUS$586k

-US$3m

Sep 30 2023n/an/a

-US$3m

Jun 30 2023n/an/a

-US$5m

Mar 31 2023n/an/a

-US$2m

Dec 31 2022US$2mUS$574k

-US$10m

Sep 30 2022n/an/a

-US$7m

Jun 30 2022n/an/a

-US$4m

Mar 31 2022n/an/a

-US$6m

Dec 31 2021US$3mUS$574k

-US$288k

Sep 30 2021n/an/a

-US$2m

Jun 30 2021n/an/a

-US$3m

Mar 31 2021n/an/a

-US$4m

Dec 31 2020US$3mUS$574k

-US$8m

Sep 30 2020n/an/a

-US$7m

Jun 30 2020n/an/a

-US$8m

Mar 31 2020n/an/a

-US$7m

Dec 31 2019US$3mUS$265k

-US$5m

Sep 30 2019n/an/a

-US$2m

Jun 30 2019n/an/a

US$432k

Mar 31 2019n/an/a

-US$819k

Dec 31 2018US$153kn/a

-US$4m

Sep 30 2018n/an/a

-US$8m

Jun 30 2018n/an/a

-US$8m

Mar 31 2018n/an/a

-US$7m

Dec 31 2017US$129kn/a

-US$2m

Compensazione vs Mercato: La retribuzione totale di Jim ($USD 2.39M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 681.57K ).

Compensazione vs guadagni: La retribuzione di Jim è aumentata nonostante l'azienda non sia redditizia.


AMMINISTRATORE DELEGATO

Jim Green (66 yo)

5.1yrs

Mandato

US$2,392,240

Compensazione

Mr. James W. Green, also known as Jim, has been the Chairman of Harvard Bioscience, Inc. since June 5, 2017 and its Director since April 30, 2015. He serves as President and Chief Executive Officer of Harv...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
James Green
President5.1yrsUS$2.39m4.38%
$ 5.7m
Jennifer Cote
CFO & Treasurer1.6yrsUS$571.27k0.097%
$ 125.9k
David Balcom
Senior Vice President of Operations2.1yrsNessun datoNessun dato
John Fry
Chief Legal Counsel & Corporation Secretary2yrsNessun datoNessun dato
Ryan Wallace
Senior Vice President of Global Sales1.3yrsNessun datoNessun dato
Lori Packer
Vice President of Global People Operationsno dataNessun datoNessun dato
David Sirois
Director of Corporate Accounting & SEC Reportingno dataNessun datoNessun dato

2.0yrs

Durata media

63yo

Età media

Gestione esperta: Il team dirigenziale di HBIO è considerato esperto (durata media dell'incarico 2 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
James Green
President9.3yrsUS$2.39m4.38%
$ 5.7m
Alan Edrick
Independent Director4.9yrsUS$213.09k0.52%
$ 681.8k
Bertrand Loy
Lead Independent Director9.8yrsUS$223.06k1.15%
$ 1.5m
Thomas Loewald
Independent Director6.8yrsUS$205.45k0.57%
$ 745.8k
Katherine Eade
Independent Director6.8yrsUS$198.09k0.61%
$ 793.1k

6.8yrs

Durata media

58yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di HBIO sono considerati esperti (durata media dell'incarico 6.8 anni).